GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » Intangible Assets

3SBio (HKSE:01530) Intangible Assets : HK$6,294 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is 3SBio Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. 3SBio's intangible assets for the quarter that ended in Dec. 2023 was HK$6,294 Mil.


3SBio Intangible Assets Historical Data

The historical data trend for 3SBio's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Intangible Assets Chart

3SBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,022.61 6,896.14 6,970.95 6,385.79 6,293.50

3SBio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,970.95 6,845.14 6,385.79 6,388.09 6,293.50

3SBio Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


3SBio  (HKSE:01530) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


3SBio Intangible Assets Related Terms

Thank you for viewing the detailed overview of 3SBio's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio (HKSE:01530) Business Description

Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
Executives
Blackrock, Inc. 2201 Interest of corporation controlled by you
Lou Jing 2305 Beneficiary of a trust
Jpmorgan Chase & Co. 2502 Approved lending agent
Hsbc Holdings Plc 2302 Custodian
Citic Securities Company Limited 2201 Interest of corporation controlled by you
Citron Pe Associates, L.p. 2201 Interest of corporation controlled by you
Citron Pe Funds Limited 2201 Interest of corporation controlled by you
Citron Pe Holdings Limited 2201 Interest of corporation controlled by you
Cpechina Fund, L.p. 2201 Interest of corporation controlled by you
Cs Sunshine Investment Limited 2101 Beneficial owner
Tmf (cayman) Ltd. 2301 Trustee
Xing Lily
Century Sunshine Limited
Decade Sunshine Limited
Lambda International Limited

3SBio (HKSE:01530) Headlines

No Headlines